Management of Canadian patients with refractory or relapsed diffuse large B-cell lymphoma in the real world: a subanalysis of the RE-MIND2 study
Results of our study support that ASCT-ineligible patients have a poor prognosis with conventional salvage chemotherapy. Before the availability of novel immunotherapies, no apparent standard of care was observed for Canadian patients with R/R DLBCL who were ineligible for or did not receive ASCT, especially after 2L treatment.
Authors
- Isabelle Fleury (ORCID: https://orcid.org/0000-0002-9301-4748)
- Zhenyi Xue
- Theresa Amoloja (ORCID: https://orcid.org/0009-0007-9629-1891)
- Anthea Peters (ORCID: https://orcid.org/0000-0002-2570-339X)
- Rosy Dabas (ORCID: https://orcid.org/0000-0002-6662-4153)
- Grzegorz S. Nowakowski (ORCID: https://orcid.org/0000-0002-6955-9393)
- Eva E. Waltl
- Caroline Koch
Institutions
- Mayo Clinic (US)
- MorphoSys (Germany) (DE)
- University of Alberta (CA)
- Hôpital Maisonneuve-Rosemont (CA)
- Alfred Nobel University (UA)
- JSS Medical Research (India) (IN)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
- Incyte (United States) (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-10-04
- DOI
- https://doi.org/10.1093/oncolo/oyaf330
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Gilead Sciences
- Celgene
- Karyopharm Therapeutics
- TG Therapeutics
- BeiGene
- Incyte
- Seagen
- MorphoSys
- U.S. Food and Drug Administration
- Kite Pharma
- Daiichi Sankyo Europe